Coversyl Plus Contraindications

Linked to perindopril: Hypersensitivity to the active substance or to any other ACE inhibitor.
History of angioedema (Quincke's oedema) associated with previous ACE inhibitor therapy (see Precautions).
Hereditary/idiopathic angioedema.
Second and third trimesters of pregnancy (see Precautions and Use in Pregnancy & Lactation).
Concomitant use of Coversyl Plus 5mg/1.25mg and Coversyl Plus 10mg/2.5mg with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m²) (see Interactions and Pharmacology: Pharmacodynamics under Actions).
Concomitant use with sacubitril/valsartan therapy. Coversyl Plus 5mg/1.25 mg must not be initiated earlier than 36 hours after the last dose of sacubitril/valsartan. (see Precautions and Interactions).
Extracorporeal treatments leading to contact of blood with negatively charged surfaces (see Interactions).
Significant bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney (see Precautions).
Linked to indapamide: Hypersensitivity to the active substance or to any other sulphonamides.
Hepatic encephalopathy.
Severe hepatic impairment.
Hypokalaemia.
Coversyl Plus 5 mg/1.25 mg: Severe renal impairment (creatinine clearance below 30 ml/min).
Coversyl Plus 10 mg/2.5 mg: Severe and moderate renal impairment (creatinine clearance below 60 ml/min).
Linked to Coversyl Plus: Hypersensitivity to any of the excipients listed in Description.
Due to the lack of sufficient therapeutic experience, Coversyl Plus 5mg/1.25mg and Coversyl Plus 10mg/2.5mg should not be used in: Dialysis patients, Patients with untreated decompensated heart failure.